TP53 and breast carcinoma: Di Minin et al. uncovered a novel cytoplasmic mutant p53 GOF in human breast cancer cells, and RAS-transformed mouse embryonic fibroblasts (MEFs), capable of altering the TNF-dependent activation of NF-κB and (c-Jun N-terminal kinase) JNK pathways through the inhibition of RasGAP Disabled 2 Interacting Protein (DAB2IP).